Checked
AEON Biopharma, Inc.
NYSE: AEON · Pharmaceutical Preparations · Aliso Viejo, CA
- Net income
- -$39.22M
- Total assets
- $5.56M
- Diluted EPS
- -$3.95
Company details
As reported to the SEC
- SEC CIK
- 1837607
- Stock
- NYSE: AEON
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 130 Vantis Drive, Suite 170, Aliso Viejo, CA 92656
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- , Emerging growth company
- Phone
- (949) 354-6499
- Employer ID (EIN)
- 85-3940478
- Last annual report
- 03/30/2026
- Last quarterly report
- 08/12/2026
Formerly: Priveterra Acquisition Corp. (until 07/24/2023)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|
| Operating income | -$12.8M | $72.98M | -$48.43M | -$1.94M |
| Net income | -$39.22M | $42.01M | -$52.56M | $8.2M |
| Diluted earnings per share | -$3.95 | $72.93 | -$0.38 | Not reported |
| Research and development | $4.09M | $14.18M | $34.75M | Not reported |
| Total assets | $5.56M | $3.14M | $10.78M | $276.9M |
| Total liabilities | $60.59M | $31.71M | $143.2M | $17.88M |
| Shareholders' equity | -$55.03M | -$28.57M | -$287.5M | -$16.93M |
| Cash and cash equivalents | $3.01M | $13K | $9.75M | $497.4K |
| Cash from operations | -$17.31M | -$20.29M | -$35.58M | -$1.49M |
| Capital expenditures | $4K | Not reported | $306K | Not reported |
Subsidiaries
1 company that AEON Biopharma, Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| AEON Biopharma Sub, Inc. | SEC 10-K |
Recent filings
112 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KRegulation FD disclosure | 10/23/2026 | 10/23/2026 |
| PRE 14APreliminary proxy statement | 10/13/2026 | 10/13/2026 |
| 8-KRegulation FD disclosure, Other events | 09/30/2026 | 09/30/2026 |
| SCHEDULE 13GOwnership report (5% holder, passive) | 08/21/2026 | None |
| 10-QQuarterly report | 08/12/2026 | 06/30/2026 |
| 8-KResults of operations, Regulation FD disclosure | 08/12/2026 | 08/12/2026 |
| 8-KRegulation FD disclosure, Other events | 08/03/2026 | 08/03/2026 |
| 8-KOther events | 07/23/2026 | 07/23/2026 |
| SCHEDULE 13GOwnership report (5% holder, passive) | 07/21/2026 | None |
| 8-KMaterial agreement, Other events | 07/15/2026 | 07/13/2026 |
| 424B4Prospectus | 07/15/2026 | None |
| EFFECTNotice of effectiveness | 07/13/2026 | None |
| S-1MEFSEC filing | 07/13/2026 | None |
| S-1/ARegistration statement (amended) | 07/09/2026 | None |
| S-1Registration statement (new securities) | 07/08/2026 | None |
| 8-KShareholder vote results | 06/17/2026 | 06/17/2026 |
| DRSSEC filing | 05/29/2026 | None |
| 8-KRegulation FD disclosure | 05/14/2026 | 05/14/2026 |
| 10-QQuarterly report | 05/14/2026 | 03/31/2026 |
| 8-KResults of operations | 05/14/2026 | 05/14/2026 |
14 insider ownership reports (Forms 3, 4, 5 and 144) were filed about AEON Biopharma, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is AEON Biopharma, Inc.'s CIK number?
- AEON Biopharma, Inc.'s SEC Central Index Key (CIK) is 1837607.
- What is AEON Biopharma, Inc.'s stock ticker?
- AEON Biopharma, Inc. trades as NYSE: AEON.
- When does AEON Biopharma, Inc.'s fiscal year end?
- AEON Biopharma, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is AEON Biopharma, Inc. headquartered?
- AEON Biopharma, Inc.'s principal executive office on file with the SEC is in Aliso Viejo, CA.
- What companies does AEON Biopharma, Inc. own?
- AEON Biopharma, Inc. lists 1 subsidiary in its SEC filings and other public records, including AEON Biopharma Sub, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026